SYK
Stryker Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth -10.5% ·
share flow -1.9% ·
net new positions -11.8%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 7 | 0 | 2.75M | $746.85M | n/a | n/a |
| Q2 2026 | 172 | +2 | 222.54M | $70.41B | +7 | −4 |
| Q1 2026 | 172 | -2 | 215.42M | $70.87B | +1 | −4 |
| Q4 2025 | 173 | -1 | 229.53M | $80.67B | +1 | −1 |
| Q3 2025 | 25 | +3 | 142.80M | $52.79B | +4 | −2 |
| Q2 2025 | 20 | 0 | 117.11M | $46.33B | +1 | −1 |
| Q1 2025 | 17 | -2 | 51.08M | $19.01B | n/a | −2 |
| Q4 2024 | 19 | 0 | 52.07M | $18.75B | +1 | −1 |
| Q3 2024 | 18 | +2 | 39.19M | $14.15B | +2 | n/a |
| Q2 2024 | 16 | n/a | 41.27M | $14.03B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 14.81M | +0.2% | $5.52B | 0.2% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 12.13M | +9.2% | $4.52B | 0.6% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 7.31M | +3.4% | $2.71B | 0.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 6.40M | -23.7% | $2.38B | 0.5% | ▼ Trim | 4 | SEC ↗ ×6 |
| 5 | Norges Bank ✦ (passive) | 5.08M | +6.8% | $1.89B | 0.3% | ▲ Add | 4 | SEC ↗ |
| 6 | Fisher Asset Management ✦ | 3.66M | -10.4% | $1.36B | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 665.30K | +9.6% | $247.66M | 0.3% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | PRIMECAP Management ✦ | 434.85K | -0.3% | $161.87M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 227.63K | +67.8% | $84.73M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 134.35K | -7.0% | $50.01M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 113.80K | +12.6% | $41.44M | 0.0% | ▲ Add | 4 | SEC ↗ ×5 |
| 12 | Millennium Management ✦ | 28.07K | -61.9% | $10.45M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 23.48K | -75.6% | $8.74M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Marshall Wace ✦ | 22.87K | +688.0% | $8.51M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 15 | GAMCO Investors ✦ | 21.72K | +0.7% | $8.09M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 16 | Bridgewater Associates ✦ | 15.48K | -61.2% | $5.76M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 9.16K | +115.6% | $3.41M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $77.14M | was 0.2% |
| Citadel Advisors | $6.53M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 2,274 holders, 283.44M shares, $87.41B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 18 sh @ 225.19 · $4,054
Director · 3 sh @ 185.65 · $557
Director · 36 sh @ 193.21 · $6,956
Director · 11 sh @ 221.03 · $2,431
Director · 63 sh @ 202.21 · $12,739
Open-market sales (S)
Officer · 441 sh · $144,915
Director · 11.26K sh · $3.81M
Director · 40 sh · $13,272
Director · 440 sh · $146,598
Director · 200 sh · $66,786
Director · 80 sh · $26,804
Director · 320 sh · $107,774
Director · 2.31K sh · $780,062
Director · 10.81K sh · $3.67M
Director · 16.61K sh · $5.66M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology